The charge of Task Group 186 (TG-186) is to provide guidance for early adopters of model-based dose calculation algorithms (MBDCAs) for brachytherapy (BT) dose calculations to ensure practice uniformity. Contrary to external beam radiotherapy, heterogeneity correction algorithms have only recently been made available to the BT community. Yet, BT dose calculation accuracy is highly dependent on scatter conditions and photoelectric effect cross-sections relative to water. In specific situations, differences between the current water-based BT dose calculation formalism (TG-43) and MBDCAs can lead to differences in calculated doses exceeding a factor of 10. MBDCAs raise three major issues that are not addressed by current guidance documents: (1) MBDCA calculated doses are sensitive to the dose specification medium, resulting in energy-dependent differences between dose calculated to water in a homogeneous water geometry (TG-43), dose calculated to the local medium in the heterogeneous medium, and the intermediate scenario of dose calculated to a small volume of water in the heterogeneous medium. (2) MBDCA doses are sensitive to voxel-by-voxel interaction cross sections. Neither conventional single-energy CT nor ICRU/ICRP tissue composition compilations provide useful guidance for the task of assigning interaction cross sections to each voxel. (3) Since each patient-source-applicator combination is unique, having reference data for each possible combination to benchmark MBDCAs is an impractical strategy. Hence, a new commissioning process is required. TG-186 addresses in detail the above issues through the literature review and provides explicit recommendations based on the current state of knowledge. TG-43-based dose prescription and dose calculation remain in effect, with MBDCA dose reporting performed in parallel when available. In using MBDCAs, it is recommended that the radiation transport should be performed in the heterogeneous medium and, at minimum, the dose to the local medium be reported along with the TG-43 calculated doses. Assignments of voxel-by-voxel cross sections represent a particular challenge. Electron density information is readily extracted from CT imaging, but cannot be used to distinguish between different materials having the same density. Therefore, a recommendation is made to use a number of standardized materials to maintain uniformity across institutions. Sensitivity analysis shows that this recommendation offers increased accuracy over TG-43. MBDCA commissioning will share commonalities with current TG-43-based systems, but in addition there will be algorithm-specific tasks. Two levels of commissioning are recommended: reproducing TG-43 dose parameters and testing the advanced capabilities of MBDCAs. For validation of heterogeneity and scatter conditions, MBDCAs should mimic the 3D dose distributions from reference virtual geometries. Potential changes in BT dose prescriptions and MBDCA limitations are discussed. When data required for full MBDCA implementation are insufficient, interim recommendations are made and potential areas of research are identified. Application of TG-186 guidance should retain practice uniformity in transitioning from the TG-43 to the MBDCA approach.
The charge of Task is to provide guidance for early adopters of model-based dose calculation algorithms (MBDCAs) for brachytherapy (BT) dose calculations to ensure practice uniformity. Contrary to external beam radiotherapy, heterogeneity correction algorithms have only recently been made available to the BT community. Yet, BT dose calculation accuracy is highly dependent on scatter conditions and photoelectric effect cross-sections relative to water. In specific situations, differences between the current water-based BT dose calculation formalism (TG-43) and MBDCAs can lead to differences in calculated doses exceeding a factor of 10. MBDCAs raise three major issues that are not addressed by current guidance documents: (1) MBDCA calculated doses are sensitive to the dose specification medium, resulting in energy-dependent differences between dose calculated to water in a homogeneous water geometry (TG-43), dose calculated to the local medium in the heterogeneous medium, and the intermediate scenario of dose calculated to a small volume of water in the heterogeneous medium. (2) MBDCA doses are sensitive to voxel-by-voxel interaction cross sections. Neither conventional single-energy CT nor ICRU/ICRP tissue composition compilations provide useful guidance for the task of assigning interaction cross sections to each voxel. (3) Since each patient-source-applicator combination is unique, having reference data for each possible combination to benchmark MBDCAs is an impractical strategy. Hence, a new commissioning process is required. TG-186 addresses in detail the above issues through the literature review 
I. INTRODUCTION I.A. Problem description
Brachytherapy plays an important role in the curative management of cancers in a variety of disease sites, 1 most prominently, gynecological malignancies, breast cancer, and prostate cancer. Commonly used radionuclides include 137 Cs for low dose-rate (LDR) intracavitary brachytherapy; 192 Ir in the form of wires or seeds in ribbons for temporary LDR interstitial implants, and 192 Ir for high dose-rate (HDR) brachytherapy. Starting in the late 1960s with 125 I seeds, 2 and continuing with 103 Pd, and more recently 131 Cs, new lowenergy (LE) radionuclides were introduced into clinical practice, revolutionizing the practice of permanent implantation. In conjunction with transrectal ultrasound (US) image guidance, LE permanent seed implantation is now one of the leading therapeutic approaches for the treatment of early stage prostate carcinoma. These radionuclides have practical advantages such as reduced shielding requirements and short halflives, making them easier to manipulate and dispose of. In addition, a new type of LE brachytherapy source has been developed: the electronic brachytherapy source (EBS), essentially a miniaturized 50 kVp x-ray tube.
The 1995 AAPM Task Group No. 43 (TG-43) report, 3 and its more recent TG-43U1 (Ref. 4 ) and TG-43U1S1 (Ref. 5) updates, are currently recognized as the worldwide standard for LE photon-emitting brachytherapy dose calculation. The TG-43 approach has been widely adopted for HDR 192 Ir remote afterloading brachytherapy dose planning. Using a table-based approach that uses a geometric dose falloff model to facilitate accurate linear interpolation on a coarse grid, the TG-43 dose calculation formalism describes dose deposition around a single source centrally positioned in a spherical water phantom. 4 The current approach for estimating doses in brachytherapy treatment planning is to superpose precalculated dose distributions for single sources in water according to the pattern of the source placement and the source dwell-time. The single-source data are derived from one-time source-model specific Monte Carlo (MC) simulations or thermoluminescent dosimetry (TLD) measurements according to specifications outlined in the AAPM TG-43U1 report, and are strictly valid only for a homogeneous water phantom of the size and shape used for data derivation. This method is fast and practical in the clinic. However, the influence of tissue and applicator heterogeneities, interseed attenuation, and finite patient dimensions are all ignored. An exception is the occasional use of one-dimensional (1D) "effective path length" algorithms 6 applied to the total dose to account for applicators incorporating high atomic number (Z) shielding materials. 7, 8 These algorithms are appropriate for the primary dose (i.e., dose contributed by direct, nonscattered photons), but fail to describe the scatter-dose component dependence on the full three-dimensional (3D) geometry. 3D scatterintegration, superposition/convolution, or transport-equation solution methods are required for acceptable accuracy. [9] [10] [11] In a 2009 Medical Physics Vision 20/20 article, Rivard et al. performed a review of the literature and concluded that accepted clinical dose parameters can be over-or underestimated by at least 5% (and by as much as factor-of-10) in numerous situations. 12 Based on the energy range, they compiled a table (Table I of that paper) describing categories of clinical applications for which the current dose calculation standard would lead to significant deviations. These effects are reviewed in more detail in Sec. I.C of the present report.
In contrast, model-based dose-calculation algorithms (MBDCAs) offer the possibility of departing from water-only geometries by modeling radiation transport in nonwater media (tissues, applicators, air-tissue interfaces), resulting in a much more physically accurate reconstruction of the dose distribution actually delivered to the patient.
I.B. Report overview and rationale
Clinical application of material heterogeneity corrections in external beam radiation therapy (EBRT) is now the standard of practice for many modalities, e.g., IMRT and hypofractionated early stage lung cancer. 13 This transition has been made possible by the emergence of MBDCAs (Ref. 14) such as collapsed-cone (CC) convolution, 15 superpositionconvolution, 16 MC methods, 17 and more recently grid-based Boltzmann solver (GBBS), 18, 19 all of which can now be found in commercial planning software packages, as well as new treatment techniques and dose-time-fractionation schedules which require a more realistic appraisal of delivered absorbed dose. In contrast, relatively little use of heterogeneity corrections has been made in brachytherapy.
From a fundamental physics perspective, the photon interaction processes, which are dominated by Compton scattering in EBRT, are more forgiving in EBRT than for brachytherapy where the photoelectric effect dominates energy deposition for LE brachytherapy sources, and to a lesser degree for highenergy (HE) sources. Thus, the all-water approximation for dose calculations is much poorer at low (E < 50 keV) and intermediate (50 keV < E < 200 keV) energies than at high energies (E > 200 keV). Even for intermediate-and HE photons, the scatter-to-primary ratio is at its maximum in materials of low Z and therefore appropriate 3D modeling of the scatter component is important. The cases of superficial implants and shielded vaginal applicators are good examples. Tissue composition heterogeneities could become critical for electronic HDR sources where mean photon energies are generally about 30 keV and the dosimetric points of interest or organs at risks (OAR) can be located many centimeters from the source.
In this context, the clinical introduction of advanced dosimetry algorithms beyond the current AAPM TG-43 formalism for sealed source brachytherapy dose calculations is highly desirable. While all of the issues mentioned previously can be tackled by MBDCAs, this adds a new layer of complexity to current treatment planning systems (TPS). In order to account for all sources of scatter and heterogeneities, accurate geometrical descriptions of the patient and implanted applicators, including assignment of cross sections to all media, must be provided on a voxel-by-voxel or component-bycomponent basis. In other words, the location and material composition of each unique geometric element considered in the dose calculation must be known. In current practice, CT images are used simply to perform anatomy delineation. For MBDCAs, the CT images will become a source of dosecalculation algorithm input data that are critical for dosimetric accuracy. Furthermore, this same information must be available for applicators, shields, and sources if intersource attenuation needs to be considered. The output of a MBDCA is highly dependent on how imaging and applicator structure information is obtained and used by the algorithm. Thus, whereas the TG-43 dosimetry formalism, despite its inherent limitations, provides the community with an intrinsic consistency in dose calculation, MBDCAs for all their advantages can lead to large center-to-center dose-calculation variations if specific guidance is not provided.
This report addresses three major issues associated with the advent of MBDCAs, namely, (1) Choice of dose specification medium (Sec. III), because there are energy-dependent differences even when nonwater materials are included in the radiationtransport model depending on whether dose is specified to a water reference medium or the local tissue medium. (2) Voxel-by-voxel cross-section assignment, as neither conventional single-energy CT nor ICRU/ICRP tissue composition recipes are de facto accurate guides for the task (Sec. IV). Each section presents its own literature review, recommendations, and related topics for future research. The report is concluded (Sec. VI) by discussing changes in dose prescription that may result from transitioning from TG-43 dose computations to more realistic MBDCA dose estimates, and the uncertainties and limitations associated with MBDCAs.
These recommendations have been reviewed by members of the AAPM Brachytherapy Subcommittee, AAPM Therapy Physics Committee, the GEC-ESTRO Brachytherapy Physics Quality Subcommittee (BRAPHYQS), ESTRO-EIR, the American Brachytherapy Society (ABS) physics committee, and the Australasian Brachytherapy Group (ABG). This report has been approved and is endorsed by the AAPM, ESTRO, ABS, and ABG. While certain commercial products are identified in this report, such identification implies neither recommendation nor endorsement by the AAPM, ESTRO, ABS, or ABG. Nor does it imply that the product is necessarily the best available for these purposes. This report is intended for the experienced brachytherapy physicist and physician considering early adoption of MBDCAs.
I.C. Review of tissue and applicator material heterogeneity effects
A short review of early literature on the impact of dosimetry from taking heterogeneity effects into account is provided below. For a more in-depth review, the reader is referred to Rivard et al. 12 Options for dose scoring/reporting and notation are summarized in Table I . Dosimetric errors incurred with the TG-43 approach and the magnitudes of differences between the various doses listed in Table I depend on photon energy. For LE sources, the photoelectric process is dominant; differences in mass-energy absorption coefficients between various tissues and water (see Fig. 1 ) 20 can result in significant dose differences depending on the medium chosen for radiation transport and energy deposition.
Note that the studies reviewed in Sec. I.C.1 compare dose calculations in homogeneous water D w,w with results of MC simulations reporting dose to the local transport medium, D m,m (cf. Table I ). More recent studies investigating the effect of using other media for dose reporting are reviewed in Sec. III.
I.C.1. Low energy regime, seeds, and miniature x-ray sources
Taylor demonstrated differences of up to 25% between D m,m and D w,w for breast tissue for the Xoft electronic miniature x-ray source with the dose ratio changing by nearly 25% over 5 cm. 21 31, 32 Two separate CT-based simulations were performed for each patient, one in which all CT voxels were assumed to consist of water and another with materials assigned according to the CT-numbers; in both cases the applicator and shielding were simulated. In soft tissues, differences between D w,w and D m,m were less than 2%. Differences between D w,w and D m,m were 18%-23% in cortical bone, 3%-3.5% in spongiosa, and 5%-7% in femoral bone.
Poon and Verhaegen found that use of D w,w-TG43 in dose calculation for breast implants (HDR 192 Ir brachytherapy) overestimated the target coverage by 2% on average, and the dose to the skin by 5% relative to TG-43.
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I.C.4. Cone beam computed tomography
Insights into dosimetry issues for extreme tissue heterogeneities, such as bone, may be obtained from MC estimates of cone-beam computed tomography (CBCT) patient dose, since CBCT energy spectra overlap the low and intermediate brachytherapy photon-energy ranges. Ding et al. 34 and Ding and Coffey 35 observed that dose to bone was two to four times greater than dose to soft tissue for a Varian OBI CBCT system (40 kVp-125 kVp with mean energy of about 60 keV); these differences are expected based on the large differences in mass-energy absorption coefficients (Fig. 1) . Walters et al. 36 reported that the elevated bone dose results in an elevated dose to bone surface cells (osteogenic cells on the endosteal surfaces), identified by the ICRP as OAR within the skeleton, due to LE electrons liberated in photoelectric events in the trabecular bone. These results indicate that skeletal doses are highly sensitive to the geometry and composition of soft-tissue cavities and bone-mineral matrix assumed, indicating that biologically relevant and accurate skeletal dosimetry is complex and may require special considerations.
II. REVIEW OF MODEL-BASED BRACHYTHERAPY DOSE-CALCULATION ALGORITHMS
This section briefly reviews model-based calculation algorithms for brachytherapy dose calculations taking into account heterogeneous geometries. While first-principles approaches (Sec. II.B) are the most accurate, the semiempirical methods reviewed in Sec. II.A address to varying degrees the clinical need for improved accuracy with high computational efficiency compared to the TG-43 method, e.g., in optimizing source placement and dwell times. A more detailed overview of calculation algorithms can be found in a 2009 Medical Physics Vision 20/20 paper by Rivard et al. 12 and in two book chapters from the 2005 AAPM/ABS Brachytherapy Summer School Proceedings. 37, 38 Collision kerma from primary photons (interacting for the first time outside the source) can be calculated using 1D ray-tracing and accurately approximates primary-photon absorbed dose under charged-particle equilibrium (CPE). CPE is valid for treatment planning of brachytherapy except very close to sources 39, 40 or to metal-tissue interfaces 41, 42 and hence the primary dose around brachytherapy sources can be derived with full accuracy using 1D methods. The scatter dose (dose contributed by photons interacting for a second time or more), depends, however, on the full 3D geometry and requires use of 3D scatter integration methods to be accurately estimated.
II.A. Semiempirical approaches
Methods that apply 1D ray-tracing with scaling for correcting total doses due to the presence of high-Z shields around 137 Cs were developed early and are also used for 192 Ir. 8, 43 Several methods of varying complexity (none, however, being fully 3D) that separate the primary and scatter dose components have been developed using 1D ray-tracing for the primary dose calculation and estimating the scatter dose component. 11, [43] [44] [45] [46] [47] [48] [49] [50] Another approach, tested for 192 Ir sources, 32, 51 is based on MC precalculated applicator-specific dose in water distributions aiming at accounting for high-Z shields but considering the patient to be water equivalent. An additional approach uses a TG-43 hybrid technique where MC calculations for rigid brachytherapy geometries are performed for input to conventional brachytherapy planning systems. [52] [53] [54] [55] [56] This technique has been performed for HDR 192 Ir gynecological implants, skin applicators, deepseated breast lumpectomy cavities, and for LDR eye plaque brachytherapy planning.
These semiempirical approaches allow brachytherapy treatment plans to be generated in the same timescales observed for conventional TG-43-based plans yet with markedly increased accuracy to represent the physical implant. Dose may be determined in any medium to any medium due to the precalculated MC dose kernels.
II.B. Model-based algorithms
Model-based approaches either explicitly simulate the transport of radiation in the actual media or employ multipledimensional scatter integration techniques to account for the dependence of scatter dose on the 3D geometry. The three methods of current interest to brachytherapy treatment planning are CC superposition/convolution, GBBS, and MC simulations.
II.B.1. Collapsed-cone superposition/convolution method
CC is a kernel superposition method designed for treatment planning applications and optimized for calculation efficiency through angular discretization ("collapsed cones") of the kernels along a radiation transport grid. 15 The kernels map the spatial energy deposition response of scattered photons and charged secondaries for a reference medium, commonly water. The common approach in EBRT, where CC has long been used, 14 is to use two kernels, one for the primary dose and one for the scatter dose, both operating on the energy released by primary photons. In brachytherapy, the approach is to calculate the primary dose through a direct raytrace of the primary photons using the kerma approximation, and use a scatter order driven process to calculate dose from first scatter and multiple scatter separately with different kernels, 9, [57] [58] [59] using the raytrace results for the primary dose as a source term for scattering. Raytracing operations are used to scale both the primary dose and all kernels for heterogeneities based on the density scaling theorem of O'Connor 60 and methods going beyond density scaling have been developed to scale kernels for heterogeneities of high atomic numbers. 58 For the primary and first scatter doses, this does not impose any approximations other than discretization effects, but is more approximate for the multiple scattering dose. The source characterization data needed for the raytracing of the primary dose can effectively be derived from precalculated primary dose distributions in water, which have motivated the suggestion of a primary and scatter separation (PSS) formalism 61 for source characterization that also provides backwards compatibility with the TG-43 tabulations. The BT collapsed cone algorithm is currently being integrated to the Oncentra Brachy TPS from Elekta (Veenendaal, The Netherlands).
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II.B.2. Deterministic solutions to the linear Boltzmann transport equation
Deterministic methods for solving the linear Boltzmann transport equation (LBTE) in integral or differential form yield approximate solutions that converge to the true continuous LBTE solution in the limit of very fine phase-space mesh spacing. There are several common approaches used, 63 including method-of-characteristics, spherical harmonics, and discrete ordinates.
Deterministic approaches solve the LBTE by systematically discretizing spatial (via finite difference or element meshes), angular (via discrete ordinates, spherical harmonics, etc.), and energy variables (via multigroup approximation), which results in a linear system of equations, which are iteratively solved. Because these methods are all based on phasespace discretization, TG-186 categorizes them as grid-based Boltzmann equation solvers (GBBS). Zhou and Inanc developed a GBBS, which they applied to LE brachytherapy, 64 based on direct evaluation of the integral LBTE, expanded in orders of scattering. Daskalov 
II.B.3. Monte Carlo simulations
The MC simulation solves the linear LBTE by random sampling and is the current state of the art in computational dosimetry. The first MC code with an advanced geometry package specific to brachytherapy sources having several nonanalog estimators (to increase computational speed) was PTRAN. 76 PTRAN can calculate the primary dose analytically and perform MC simulations for the scatter dose part. 2, 77 For treatment planning applications increasing computational efficiency through correlated sampling has been investigated. 78, 79 Chibani and Williamson have presented a fast MC code intended as a dose calculation engine for LE brachytherapy seeds. 80 BrachyDose is an extension to EGSnrc allowing for use of a track-length estimator and modeling of clinical sources. 81, 82 GEANT4 has also been used for postimplant treatment planning. 25 Most brachytherapy treatment planning applications are based on the assumption of CPE and implement the equivalence of absorbed dose and collisional kerma using track-length estimators, and may employ phase-space files to characterize sources before "run-time." Further references to such applications are given in Sec. III. The readers are referred to Sec VI.A for a discussion of the differences between MC and GBBS.
III. DOSE SPECIFICATION MEDIUM SELECTION
MC simulations and other MBDCA methods offer the possibility of realistic modeling of the absorbed dose distribution in patient treatment geometries, including the impact of applicator materials, skin surface contour, and deviation of tissue composition and density from those of liquid water. As in megavoltage EBRT, 83, 84 modeling radiation transport in nonwater media confronts the medical physicist with another decision: the selection of dose specification medium. Absorbed dose can be reported either to the local tissue composing each voxel, D m,m , or to a fixed reference medium (usually but not necessarily water), D w,m , regardless of the composition of the underlying voxels. As summarized in Table I , choices for absorbed dose estimation at location r may be represented by D x,y-Z (r) where: x denotes the choice of dose-specification medium (either water or local medium at r); y denotes the choice of voxel composition assignment used to perform the radiation transport or scatter-integration calculations (cf. Table I ); and Z denotes the algorithm (either MBDCA or TG-43). In the TG-43 protocol, both the transport geometry and the dose-specification medium are taken to be water:D w,w-TG43 (r).
Choosing between the competing D w,m and D m,m alternatives in brachytherapy parallels the controversy this issue has engendered in megavoltage EBRT planning; arguments from the EBRT debate are briefly reviewed in the present paragraph. [83] [84] [85] For EBRT, one argument for reporting D w,m is maintaining consistency with earlier calculation methods that reported dose to water. 83, 84 A more recent argument in support of D w,m reporting is that the biological targets of interest, i.e., cells or cell nuclei, consist mainly of water 85, 86 and are likely to vary less between tissue types due to their functional similarity than the tissue-averaged composition. 85 however, it recommends that publications clearly state which quantity is reported and provide information to allow conversion between them. These conversions of D m,m to D w,m and vice versa employ Bragg-Gray (small cavity) theory and ratios (water to medium) of mass collision stopping powers (e.g., see review in TG-105 report 85 and recent discussion by Ma and Li 87 ). With the exception of specifying clinically meaningful doses to bone, 88 the controversy regarding the medium for dose specification in EBRT is largely academic since the differences between D w,m and D m,m are limited to 2% for all soft tissues, [89] [90] [91] [92] with similar results obtained for proton beams. 93 Somewhat different issues need to be considered in selecting the dose-reporting medium for brachytherapy and other keV photon field applications. While secondary charged particle ranges of the order of several centimeters are common in megavoltage photon EBRT, they are much shorter in photon brachytherapy (cf . Table II) . Thus, in brachytherapy, CPE is generally a valid assumption for dose calculations using common treatment planning voxel grids. Under CPE, absorbed dose equals collision kerma and can be approximated by kerma since brachytherapy energies are suffi- 
where K coll and K denote collision kerma and kerma, respectively. In EBRT, cellular and subcellular biological targets can be considered small cavities with small dimensions in relation to secondary charged-particle range; this is not generally the case in brachytherapy. In addition, LE brachytherapy dose distributions are highly sensitive to the atomic compositions of media ( Fig. 1) .
In EBRT, unrestricted mass collision stopping power ratios are often used to convert D m,m into D w,m , an approach that is valid only if the water cavity is a Bragg-Gray cavity, i.e., small enough to not perturb the fluence of secondary electrons generated in the medium. Although the appropriate water volume (cavity) size remains to be determined, the Bragg-Gray assumption implies that these cavities are much smaller than the 3-5 mm-sized voxels typically used for dose calculation, e.g., cavities may represent cellular structures or micrometer-size radiosensitive targets (e.g., soft tissue structures within trabecular bone). 36, 86, 88 In the context of proton therapy, Paganetti discussed the conversion of dose to a patient voxel (of local medium) to dose to water for an infinitesimal volume of water within that voxel. 93 While D w,m may be computed on-the-fly for some MC dose codes, e.g., by multiplying the energy loss from each electron condensed history step by the water-to-medium ratio of restricted mass collision stopping powers, the conversion of D m,m into D w,m is typically performed as a postprocessing step which occurs after calculation of D m,m on a mm-sized voxel grid. 85 The ranges of secondary electrons set in motion by photons from brachytherapy sources are generally shorter than those for EBRT and vary considerably between the different brachytherapy energy regimes (see Table II for continuous slowing down approximation (CSDA) ranges of electrons in water for electron energies between 10 keV and 3 MeV). 94 If radiation target volumes ("cavities") are considered to be macroscopic millimeter-sized voxels, then the range of secondary electrons may generally be considered short in comparison with the cavity size (for 192 Ir energies and below); hence large cavity theory using ratios (water to medium) of mass-energy absorption coefficients could be used for the postprocessing D m,m to D w,m conversion; direct computation of D w,m using the collision kerma approximation should yield identical results. While a cavity of cellular dimensions might be considered "Bragg-Gray-like" for 192 Ir at 380 keV or for MeV photons (EBRT), the situation is different below 50 keV: cellular dimensions are comparable to the ranges of secondary electrons (mammalian cell diameters are generally of order 10-20 μm; cell nuclei diameters range from a few micrometers to upwards of 10 μm), 95 rendering both large and small cavity theory assumptions suspect. For example, for 125 I sources, secondary electron ranges vary from 3 to 20 μm (Table II) . Thus, depending on the size of an assumed biological target in relation to photon energy, different calculation techniques are required to compute D w,m . In addition, for LE brachytherapy the two quantities D w,m and D w,w-TG43 differ considerably regardless of the method used to compute D w,m (see Sec. III.A) and hence, for this energy regime, one cannot motivate reporting D w,m to connect with previous clinical experience. However, for HE brachytherapy sources, the situation is more similar to EBRT.
Sections III.A and III.B discuss the relationships between D m,m and D w,m in the context of cavity theory. Section III.A focuses on the large cavity regime and reviews recent publications which compare D m,m and D w,m under this assumption. This is followed in Sec. III.B with a cavity theory analysis of cellular and subcellular target dosimetry and a discussion of issues related to the choice of dosimetric medium, based on ongoing and recent research by Thomson et al. 96 and Enger et al., 97 designed to determine which choice of macroscopic dose specification medium might better correlate with absorbed dose to biologically relevant cellular or subcellular targets. After reviewing the scientific research in 
where D targ (r) denotes the absorbed dose to the biologically relevant target at location r. Equation (1) assumes both that this target cavity is water equivalent and that its minimum linear dimension is large in relation to the secondary electron ranges.
Large differences between D m,m and D w,m are expected for certain media at low energies based on the behavior of massenergy absorption coefficients at low energies (Fig. 1) , an expectation confirmed by recent studies.
27, 98-100 Differences between D m,m and D w,m are most significant for photons below 50 keV and can be as high as 70%-80% for soft tissues, rising up as high as a factor of 7 for bone. 98 103 Pd, 131 Cs, and an electronic brachytherapy source operating at 50 kV) do not vary significantly with distance from the source for distances up to 6 cm in a variety of tissues (adipose, mammary gland, prostate, muscle, skin). 98 Differences between D m,m and D w,m are within 3%-5% for soft tissues at the higher 192 Ir energy, rising to around 15%-25% in bone. 99 For biological targets having dimensions on the order of 10 μm, it is only for the lowest energy sources that the large cavity theory may make biological sense. 97 For higher energy 192 Ir and 137 Cs sources, the large cavity assumption implies that targets have dimensions on the order of 1 mm and thus excludes the interpretation of the target being the cell or a part thereof.
III.B. D m,m and D w,m relationships in the small and intermediate cavity regimes
For a water-equivalent target that is much smaller than the secondary electron range, located at position r, and surrounded by a homogeneous nonwater medium of macroscopic dimensions, the absorbed dose to the target is
where (S col (r)/ρ) w m is the average over the photon energy fluence spectrum of S col (E, r)/ρ, the mass collision stopping power averaged over the slowing-down spectrum arising from secondary electrons liberated by collisions at r of photons with energy E. Equation (2) was derived using the fact that (S col (E)/ρ) m w is independent of electron energy to first approximation (Fig. 2 , generated using the EGSnrc usercode examin 101 ). Unlike the large cavity conversion factor (μ en (r)/ρ) w m [Eq. (1)], which can vary by as much as an order of magnitude from one tissue to another for LE brachytherapy (Fig. 1) , the small cavity conversion factor, (S col (r)/ρ) w m , deviates from unity by no more than ±5% for soft tissues over the brachytherapy energy range. Except for the very lowest energies where biological targets of the order of 2-10 μm are comparable to secondary electron ranges, Eq. (2) suggests that for kerma-based MBDCAs, K m,m is a more logical quantity to score than K w,m .
A review of cellular morphology (size and composition of cellular components) reveals that nuclei and cytoplasm contain significant mass fractions of proteins, inorganic elements (ranging from sodium to calcium), and lipids (adipose cells only) and that these fractions vary widely with cell type. 96 Values of (μ en (r)/ρ) w m for cytoplasm and nuclear media (for many soft tissues and tumor types) deviate from unity (up to 10%) for 103 Pd and 125 I spectra. Hence, cell targets may not generally be assumed to be water equivalent.
Enger et al. used Geant4.9.4 to score dose to 14 μm diameter cavities consisting of either water, cell nucleus medium, or soft tissue embedded in small phantoms composed of uniform soft tissue, to compute D w,m , D n,m (where "n" represents cell nucleus medium; cells were not explicitly modeled), and D m,m , respectively. 97 For source energies between 20 keV and 300 keV, it is reported that D w,m is a "good substitute" for D n,m for the soft tissues (breast, prostate, muscle, adipose) and the four cell nucleus compositions considered under the assumptions used in the simulations. It was concluded that there is a need for more data on tumor and healthy tissue cell compositions as doses to the cavities of nuclear media depend on their composition. Further investigations of issues related to cell dosimetry for brachytherapy likely require accurate simulation of media surrounding the nucleus as many electrons depositing dose in the nucleus are set in motion outside it. To this end, research by Thomson et al. involved Monte Carlo simulation of clusters of cells including cell nuclei, cytoplasm, and extracellular fluid. 96 Their results (full paper under review August 2012) suggest that doses to cell nuclei are sensitive to the presence of the different media surrounding the nucleus (e.g., cytoplasm, extracellular fluid); nuclear doses and their relation to D w,m and D m,m depend on many factors including cell and nucleus size, cellular and bulk tissue compositions, and source energy.
The complexity of the relationship between macroscopic and biological target doses is well illustrated by adipose cells. Such cells have a very large diameter, typically 100 μm, with each cell containing approximately 96% lipid, 2% intracellular water, and 2% electrolytes and protein. An idealized model of a fat cell might consist of a 33 μm thick spherical shell of lipid, enclosing a 34 μm diameter cytoplasmic cavity which in turn surrounds a 3 μm nucleus. Suppose that the relevant biological target is the nucleus. For photons with energies less than 50 keV, this is a very complex situation in which the target can approximately be modeled as a BraggGray cavity, but where secondary electrons arise from photon collisions in two different compartments (lipid droplet or cytoplasm). These compartments have significant compositional differences resulting in more than a twofold reduction in the cytoplasmic (μ en (r)/ρ) m w ratio in the 103 Pd-125 I energy range, with deviations exceeding 10% persisting at energies as high as 90 keV. This complex situation is reminiscent of the two-component thick-wall ion chamber problem solved by Almond and Svensson. 102 Following this approach:
where D nucl is the dose to the target nucleus, α is the fraction of electron fluence crossing the nucleus (=nucl) arising in the lipid shell (=lip) and (1-α) is the corresponding fraction arising from the cytoplasmic shell (=cyto). Invoking the approximations that nucl ≈ cyto ≈ wat and m ≈ lip, Eq. (3) becomes
Even in this simplistic approximation, D targ is the weighted average of a correction that is as large as two with one that is approximately 0.95, with weighting factors that vary strongly with energy and cellular dimensions. An even more complex analysis would arise if one were to treat the nuclear target as an intermediate size cavity by means of Burlin cavity theory. In this scenario, only MC methods capable of transporting both photons and secondary electrons through a complete microscopic-scale geometric model could quantitatively estimate a biologically meaningful target dose. While research investigating relations between macroscopic medium dose and cellular absorbed doses and employing MC methods is ongoing, 96, 97 this example clearly shows that it is premature and potentially misleading to conclude that either the small or large cavity models can be naively applied to water-equivalent targets if the goal is to maximize the correlation between the macroscopic dose descriptor and biological effectiveness.
III.C. Recommendations
The scientific literature reviewed in Secs. I.C, III.A and III.B reveals that the adoption of MBDCA for brachytherapy will generally change reported doses compared to the previous water-based dosimetry practices (e.g. 
III.D. Areas of research
To address the underlying scientific question stated above, namely, the question of which dose specification approach maximizes the correlation between macroscopic dose and dose to biological targets, further studies on the relationship between radiobiological target doses as functions of target geometry, cellular anatomy, and tissue anatomy are needed.
Through such studies, the optimal choice of dose specification medium, D x,m , as well as a method of estimating this quantity from photon energy fluence or D m,m may be identified. Current efforts 36, 88, 96, 97 use idealized cell or tissue models and coupled photon-electron MC techniques to study relations between D m,m and dose to biological targets. Future research should include complex multicomponent and multicellular models in which the assumptions of uniformity and target isolation (used in the discussion of Sec. III.B) break down. Investigators conducting such studies should clearly specify the conversion method used in going from D m,m into D w,m . Reporting conversions from D m,m into D w,m using both stopping power ratios and mass-energy absorption coefficient ratios could be interesting since potential conversion methods probably lie somewhere between these two and likely depend on the tissue or organ in question, as well as the photon spectrum and biological endpoint. As target composition and size vary from tissue-to-tissue as well as clinical endpoint, it may be appropriate to treat dose specification as an organ-and clinical-endpoint specific K m,m to D targ postprocessing conversion in the same spirit with which absorbed dose is converted to biologically equivalent dose (BED) using variable linear-quadratic model parameters.
Comparisons of D m,m and D w,w-TG43 for different source energies and biological tissues are necessary for the recalibration of prescribed and reported doses, especially for LE sources. Investigations of doses to skeletal tissues, radiosensitive bone marrow, and to biologically important subcellular structures in adipose tissue are needed.
IV. CT IMAGING AND PATIENT MODELING
IV.A. Literature review
MBDCAs generally require assignment of interaction cross sections on a voxel-by-voxel basis to compute dose. The information is taken into account in dose calculations for HE photons by using the electron densities ρ e (or the mass densities ρ) from CT images. 103 At high energies, Compton scatter dominates and depends mostly on ρ e (e − /cm 3 ) = ρN A Z/A. The ρ e can be extracted by using a calibration procedure using a phantom with known composition.
In brachytherapy, the dose is administered by photons with energies <1 MeV. The lower the photon energy, the larger the differences between media in terms of mass-attenuation and mass-energy absorption coefficients due to the increasing importance of the photoelectric cross section, which is approximately proportional to the cube of Z and inversely proportional to the cube of the photon energy. Human tissues are essentially water-equivalent for dosimetric purposes for MV photon beams and HE sources such as 137 Cs and 192 Ir, 104 but not so for LE sources such as 103 Pd, 125 I, and 131 Cs, and EBS. 50, [105] [106] [107] Hence, for accurate LE photon brachytherapy dosimetry, knowledge of tissue mass (electron) density and the atomic number distribution of the material is crucial. 108 In this report, "segmentation" is defined as the spatial delineation of different regions of a 3D image dataset and assignment of elemental compositions and mass (or electron
4 is based on a water geometry with a fixed mass density.
IV.A.1. Material characterization
Breast tissue is known to vary widely in its mix of adipose and glandular tissue. ICRU-46 (Ref. 109 ) lists the two tissues as mainly differing in their carbon content (glands: 33%, adipose: 60%) and oxygen content (glands: 53%, adipose: 28%). The effective atomic number, Z eff , is 6.67 for average adipose tissue and 7.27 for average glandular tissue. 110 Therefore, for dosimetric purposes with LE photons adipose and glandular tissue behave very differently and it is important to be able to distinguish them. Recently, a study of several thousand women who received mammography or breast CT exams revealed a population average of about 20% for the volume breast density (VBD, defined as the fractional volume of glandular tissue), contrary to the commonly assumed 50%. 111 The study also showed that VBD ranges from 0% to 75%.
A topic that deserves special attention is calcifications in prostate and breast. Prostate calcification may be present in a significant number of patients. 39, 112 Using MC simulations, a preliminary study was performed to assess the dosimetric effect of calcification in prostate. 23 The authors were unable to find a reliable reference on the composition and density of calcifications in the prostate; therefore, they used breast calcifications from ICRU Report 46 as a surrogate. 109 They reported a decrease of up to 37% in the CTV D 90 dose metric. Another study found that the CTV D 90 parameter was lower than estimated by up to 17 Gy (about 12% of the 144 Gy prescription dose). 25 More recent pathological measurements of calcifications in prostate have been reported. 112 Another medium that may need to be specified accurately is the imaging contrast agent. Kassas et al. 113 looked at the effect of iodine-based contrast medium on dose calculations for HDR 192 Ir partial breast irradiation with the MammoSite R system. At 1 cm away from a 6 cm diameter balloon, they obtained a dose decrease of 5.7%. Metals and other materials used in applicators and shielding also need to be assigned correctly. This is often done by using an explicit solid model of the applicator/shielding that is added to the tissues extracted from the images. One recent example of this procedure is the MC dose calculations for a shielded colorectal cancer treatment. 31 More examples can be found in the literature. 51, [114] [115] [116] Yet another issue of potential importance is the presence of edema in the prostate and breast, and its changing influence on the dose over time. 117 Although considered to be largely water-equivalent, more studies of prostate composition and volume variation are warranted.
Recently, Landry et al. studied in detail the tissue composition/density sensitivity of MC dose calculations for LE brachytherapy. 118 Tissue composition reported in the literature varies depending on the reference. For example, the carbon content of breast adipose tissue, which largely determines its effective atomic number and, therefore, the fraction of photoelectric versus Compton events, has been reported to vary between 52% and 68%, 110 leading to variations in effective atomic number of 6%. Similarly, for prostate tissue the carbon content reported in the literature varies widely between 9% and 26%, leading to effective atomic number variations of only 2%. More results are discussed in Landry et al. 118 For HDR 192 Ir brachytherapy of gynecologic cancers with standard CT/MR compatible applicators (no shielding), MDBCA has little impact (<5%) compared to TG-43 for most clinical parameters. 121, 122 
IV.A.2. CT segmentation
In HE photon radiotherapy, patient heterogeneities are modeled by ρ e derived from CT data. The accuracy of this approach depends on the reliability of the Hounsfield Units (HU), which are calibrated using tissue substitutes. The latter have to be used with care in brachytherapy as they often are designed to be tissue-equivalent only for HE photon dosimetry. In MV dose calculations, large HU errors can be tolerated before dose errors of a few percent are produced. 123, 124 See also AAPM Report No. 85 by Papanikolaou et al. 13 A more sophisticated tissue segmentation method has been introduced-the stoichiometric method-to take into account the atomic composition of the phantom materials used for CT calibration. 125, 126 The measured HU of tissue substitutes are used to determine linear attenuation coefficients as a function of ρ e and atomic number for the CT photon spectrum. This relationship is used to predict HU for tissues with known relative ρ e for photon dosimetry. This method allows the patient CT data to be used directly in the treatment planning calculations without the need for segmentation and identification of specific tissue types. However, the accuracy of this method for LE photon dose calculations is unknown.
It is generally accepted that MC dose calculations are the most accurate for photon radiotherapy. The majority of MC codes require that in addition to mass or ρ e , a medium needs to be assigned to all voxels. Media assignment errors may lead to dosimetric errors in MC and other MBDCA calculation methods, which can cause large dose errors compared to simply assigning all voxels to water with a variable density. A sensitivity study was performed for CT image use in MC dose calculations for 250 kVp-15 MV photons. 127 The authors found that inaccuracies in tissue segmentation caused dose errors of more than 40% in certain media in 250 kVp beams. These large errors occurred in CaCl 2 solutions, mimicking bone. Schneider et al. 128 showed that many different tissues have similar HU values (between −100 and +100) and hence cannot be readily resolved. They introduced a model where all skeletal tissues are composed of a mix of osseous tissue and bone marrow, and all soft tissues are a mix of fat and water. Other studies on HE photon dosimetry have been published. [129] [130] [131] For LE photons, HU studies are rare. Watanabe derived linear attenuation coefficients from HU for LE brachytherapy MC dose calculations. 132 They introduced a model that relates HU to ρ e and Z eff accounting for both photoelectric absorption and Rayleigh scatter. Their technique led to errors of 10%-20% for the elements O, C, and Ca, and is only a moderate improvement over the older Rutherford formalism for high-Z media such as bone. 133 These authors did not investigate the ensuing effect on dose calculations.
It appears that the direct extraction of interaction coefficients for LE photons from CT images is an ill-studied subject. More accurate tissue determination may be possible with monoenergetic synchrotron x-ray CT scanners, 134, 135 but this remains far from an established clinical technique. Advantages would be reduced beam-hardening artifacts and possible energy tuning to match either patient dimensions or the K-edge of a contrast medium. 134 
IV.A.3. CBCT segmentation
A similar issue is the extraction of tissue information from cone beam CT (CBCT) scanners used in the treatment room. The advantage is that information on patient geometry and composition can be obtained at treatment time, which may be different than the information at the stage of CT scanning due to various factors such as weight loss, different organ filling. 136, 137 CBCT scanners have been investigated to some extent for EBRT, both for kV and MV-CBCT, [138] [139] [140] but not yet for brachytherapy. This discussion is limited to kV-CBCT as appropriate for brachytherapy. The imaging quality in a kV-CBCT scanner is inferior to a regular fan-beam CT scanner due to increased photon scatter intercepted by the larger 2D detection panel leading to reduced imaging contrast, increased cupping, and streaking artifacts. 139 Therefore, calibration of the kV-CBCT scanner in terms of HU versus ρ e is essential for dose calculations. 138, 140 On the other hand, the spatial resolution of the CBCT scanner in the axial direction is superior to a fan beam CT scanner.
A study using a kV-CBCT scanner and several calibration phantoms reported that the accuracy of EBRT dose calculations-based CBCT images of phantoms and patients was within a few percent of dose calculations based on images from a fan beam CT. 140 In contrast, more recently Hatton et al., 138 also studying a kV-CBCT scanner attached to a linear accelerator, found that phantom size substantially influenced the HU. Compared to CT-based dose calculations, this led to large dose errors of up to 20% for 18 MV x-rays in bone.
In brachytherapy, the use of a CBCT scanner in the treatment room has been investigated to a limited extent, e.g., to investigate the possible use a CBCT scanner for conventional TG-43 dose to water calculations in HDR cervix treatment. 141, 142 Dose to medium calculations in brachytherapy based on kV-CBCT imaging has not been attempted yet. HU calibration in kV-CBCT seems an issue that deserves more attention and CBCT images should not be used for brachytherapy dose calculations when tissue heterogeneity information needs to be taken into account.
IV.A.4. Dual energy CT and spectral CT
Nearly 40 years ago, it was proposed that dual-energy CT (DECT) may allow extraction of tissue characteristics in a more accurate way than single-energy CT. 133, 143 In a similar vein, multienergy CT, or spectral CT, was recently advocated to allow more accurate tissue composition extraction. [144] [145] [146] The DECT technique is now best known for the determination of bone density. 147 It may also be used to measure arterial calcifications, 148 or breast composition. 149 The DECT underwent steady development since its inception, 150, 151 which led to research systems and clinically available products. 134, 152 The DECT technique utilizes two x-ray CT images acquired using two well-separated x-ray energy spectra. This then allows obtaining an image of the mass or electron densities (i.e., morphology) and another image of the atomic numbers of the geometry (i.e., chemical composition), which greatly aids in identifying tissue types. DECT can also be used to aid extraction of photon interaction coefficients more accurately than single energy CT. 108 DECT was used to extract tissue data needed for MC treatment planning for MV and kV photon beams. 153 Spectral CT may help to extract even more tissue information than DECT.
To our knowledge, only one study attempted to use DECT for brachytherapy. The investigators proposed a method to estimate voxel-by-voxel the distribution of the photon interaction coefficients for brachytherapy energies. 108 They used two methods: a parametric fit model and a basis vector model, of which they recommended the latter. No brachytherapy dose calculations were shown in this study. Vigorous research efforts are ongoing in DECT and spectral CT. 146 It may well constitute an improvement over single-energy CT to derive tissue characteristics for brachytherapy dose calculations, but much research is needed to establish the technique for this purpose. Two recent studies showed that DECT could segment tissue phantoms more accurately than single energy CT.
154, 155
IV.A.5. CT artifacts
The CT artifacts may lead to differences between true and reconstructed photon interaction coefficients. The presence of high-Z, high-density materials in a scanned object will lead to streaking artifacts which may severely degrade image quality. Examples specifically for brachytherapy are the presence of metal applicators, vaginal packing, or radioactive seeds. Usually, those metallic objects are very close to, or even within, the target volume. Hence, without artifact correction, it is impossible to accurately assess ρ e and the composition of some voxels. Streaks not only prevent accurate structure delineation but may also cause dose miscalculation. This is particularly true for MDBCA dose calculations in brachytherapy, which may be more sensitive to incorrect media assignment than other dose calculation algorithms.
A variety of artifact correction techniques have been developed to improve image quality. The simplest approach that can be used for minor artifacts is to correct the discrepancies in the CT images themselves. 156 More sophisticated approaches use one of three main techniques: filtered back-projection on a modified sinogram, [157] [158] [159] filtering techniques, 160 and iterative algorithms. [160] [161] [162] [163] [164] [165] The modified filtered back-projection methods often involve interpolation in the sinogram domain after high-density objects have been removed. The impact on MC dose calculation accuracy was assessed for a double-hip prosthesis case. 166 For an 18 MV photon dose calculation, the dose differed significantly in the corrected and noncorrected CT geometry. This technique was also used to reduce imaging artifacts in the presence of a Fletcher-Suit applicator for HDR brachytherapy, 158, 163 but these authors did not perform dose calculations. Recent studies have looked at correction methods for metallic LDR seed implants using post processing algorithms on CT slices, virtual sinogram technique, or the more efficient approach processing the raw sinogram data. 27, [167] [168] [169] The presented preliminary dosimetric results indicate that artifacts can lead to large discrepancies. 27, 167 It is clear that CT artifact correction should also be encouraged as a field of research to improve brachytherapy dose accuracy.
IV.A.6. Other imaging modalities
Volume delineation based on imaging modalities other than CT can be performed, especially when the lack of electron density information is not a significant problem, e.g., for a homogeneous dose calculation. Contours drawn using MRI could suffer from image distortion but can still be used successfully in brachytherapy planning [for example, prostate 170 or GYN (Ref. 171 ) treatments]. Image fusion with CT often offers the best results. 172 Also, US imaging has been used to outline organs in brachytherapy. In particular, transrectal US imaging is commonly used to perform LDR prostate seed implants. [173] [174] [175] This technique clearly visualizes the prostate and the urethra, but the act of imaging the organs deforms them. The consequences for dosimetry are not well understood. Three-dimensional US imaging with external US transducers offers possibilities for noninvasive imageguided brachytherapy for prostate, cervix, and breast without geometric distortion, although these techniques are currently rarely used for brachytherapy. 176, 177 However, none of these techniques can presently provide information on tissue heterogeneities as would be required within the scope of the current task group report. In US techniques, contrast-enhanced imaging 178 and tissue typing 179 are active fields of research, which may also play a future role in brachytherapy.
IV.B. Recommendations
IV.B.1. Consensus material definition
The number of materials should be limited to a few. For prostate and breast, there is still disagreement on the composition to be used, so more tissue composition studies are required. The mass density derived from the CT scanner image should be used, but special measures should be taken if metal streaking and other CT artifacts are present. is recommended for the whole breast, corresponding to the mean gland and adipose compositions reported in the literature (Table III) . From the breast CT HU, the mean overall breast density may be extracted from which the relative mass fractions of adipose and glands may be derived (see Sec IV.B.2). Using a generic breast composition is not recommended due to the large spread in breast tissue composition in the population. 180, 181 If no information at all can be extracted from the CT images, then we recommend using a 20% glandular/80% adipose composition (fractions by weight) as a population average. 111 
IV.B.1.c. Calcifications.
The literature is sparse on the composition of calcifications as may be present in breast and prostate. Chibani and Williamson performed MC calculations for calcified prostate. 80 They assumed that prostate calcifications are similar to breast calcifications for which they used the composition reported by the ICRU 46 report. 109 This report lists as constituents of breast calcifications hydroxyapatite, tri-calcium phosphate, and protein (e.g., their MBDCAs require explicit specification of geometry, atomic composition, and density of all nonwater materials, including the internal structure of sources and applicators that can influence the dose distribution. In contrast, the end user of TG-43 single-source dose distributions need not directly validate the source geometry used by a MBDCA since source structure is implicitly included in the dose-rate measurements and MC calculations from which the TG-43 parameters are derived. As long as single-source MBDCA calculations are carefully validated against published TG-43 models, one can consider the MBDCA geometric assumptions indirectly but adequately validated. However, because reference-quality dose-rate distributions for each potential source-applicator combination are lacking, indirect dosimetric validation of MBDCA shielded applicator geometries is not a feasible strategy. The possibility that source and applicator geometry models in the planning system may not accurately describe the devices actually used in the clinic creates new and highly significant error pathways. This may affect treatment outcomes of many patients to the extent that completely ignoring source/applicator geometries could be less deleterious than making clinical decisions based upon inaccurate models. To guide both vendors and early adopters of MBDCAs, the Task Group makes the following recommendations:
(1) It is the responsibility of the end-user clinical physicist to confirm that MBDCA dose predictions are based upon sufficiently accurate and spatially resolved applicator and source models, including correct material assignments, to avoid clinically significant dose-delivery error prior to implementing the dose algorithm in the clinic. (2) Patient CT grids, which typically have cubic spatial resolutions no better than 1 mm, are not adequate for accurate modeling on the spatial scale of brachytherapy sources and applicators. Dose distributions from LE sources are particularly sensitive to simplistic geometric approximations. MBDCA vendors should use analytic modeling schemes or recursively specify meshes with 1-10 μm spatial resolution as required to accurately depict LE seed geometry. Otherwise, nuances of seed geometry will be lost and resultant dose distributions will be in error. (3) With regards to MBDCAs, the Task Group takes the position that it is the responsibility of the manufacturers of seeds and applicators to disclose their geometry, material assignments, and manufacturing tolerances to both end users and TPS vendors (if responsible for data entry and maintenance), as this information is needed to accurately model dose around these devices. The device vendor disclosure must have sufficient detail to enable the end user to verify correct entry into the TPS. Furthermore, it is the responsibility of the TPS vendors to incorporate the device in the system or provide a simple means to the end user to do so. (4) Prior to accepting a device vendor's disclosed source or applicator geometry for clinical application, it must be verified by an independent investigator (as defined by TG-43U1). As described by TG-43U1 appropriate verification techniques include transmission radiography and autoradiography, direct mechanical measurements, microphotography of disassembled applicator/source components, and electron microscopy of source components. MC parametric studies can be used to assess significance of geometric uncertainties. 165, 182, 183 If a peer-reviewed publication of the applicator or source geometry of interest is not available, the responsibility for performing the independent assessment falls to the end user. (5) TPS vendors are nowadays increasingly providing libraries of applicators, which will ease the verification task. When such libraries are provided, it is the responsibility of the vendor to also provide visualization or reporting tools that enable the end user to verify the correctness of each included applicator and source model against independent design specifications. In addition, TPS vendors must disclose sufficient information to the user regarding the model or recursive mesh generation to allow verification of the spatial resolution requirement specified in recommendation (2) . (6) For each individual source model used clinically, during commissioning, the end user should compare MB-DCA single-source dose distributions in water to directly calculated TG-43 benchmarks as described in Sec. V.B. TPS vendors should disclose the dose calculation grid sizes used and provide tools to correct for volume averaging near sources so that unambiguous comparisons between TG-43 and MBDCA dose distributions can be performed.
It is the intention of the joint AAPM/ESTRO/ABG Working Group on MBDCA to provide benchmarking data on a registry to assist with the verification process as stated in Sec. V.C.2.
IV.B.2. Material assignment method
For any application of brachytherapy dosimetry in nonwater media, tissue composition is required to compute dose. For a given organ, it is recommended that the tissue composition assignment be guided by contours approved by the radiation oncologist. In case CT images are available, for all voxels inside a given contour we recommend using the CT derived densities with a uniform tissue composition. TG-186 recommends the mean tissue compositions listed in Table III . These should be used whenever possible. In case different compositions than the recommended ones in Table III are used, calculations should also be provided with the recommended compositions to allow intercomparisons.
In any publication for which the results depend on material heterogeneities, each material composition must be specified and its origin described, e.g., citation from the literature or the authors' determination. For each material, either the mass density assumed shall be specified, or if derived from CT imaging (recommended approach), the scanner calibration method and HU-to-density and/or composition conversion technique shall be described. For the latter, the CT calibration curve depends on the CT x-ray tube kV value that is used; the appropriate calibration curve for the kV used to record the images shall be reported. However, before relying on CT-to-density conversions clinically, the confounding influence of residual streaking artifacts must be ruled out. If imaging artifacts are present, we recommend a complete override of the tissue in question with a uniform density, which may be the average of neighboring pixels. For prostate seed brachytherapy, it may be prudent to rely on the density from a preimplant CT that is free from metal artifacts.
Typical CT simulators have calibration curves for HU versus electron density relative to water, ρ e,rel , with the latter defined as
where N g stands for the electron density per unit mass (#e-/g), and the subscript w denotes water. Since N g for bodily tissues, taken from ICRP23 (Ref. 119 ) and listed in Schneider et al., 126 vary little over the whole range of human tissues (standard deviation 2%), the relationship between ρ and ρ e,rel is nearly linear. When all the tissues (excluding "inflated lung") are fit to a straight line, the following relation is obtained:
which has a maximum error of less than 1% (ρ e,rel is dimensionless, ρ is in g cm −3 ). For "inflated lung" usually ρ = 0.26 g cm −3 or ρ e,rel = 0.26 is used. A possible exception to filling structure contours with a single uniform tissue might be breast. If adipose and glandular tissues can be distinguished in the CT images, e.g., by a thresholding algorithm, or by registration with another imaging modality, the regions segmented as either adipose or gland may be assigned with their proper mean composition (Table III) and voxel mass densities. 181, 184 If the adipose and glandular regions cannot be distinguished reliably, then the whole breast should be assigned to a uniform medium, which should be a mix of adipose and gland, since it is well known that a wide, age-dependent range of mixes exists among the female population. 111 From the breast mean mass density ρ obtained from the CT scan and the known (or assumed) mean mass densities for adipose ρ A and glandular tissue ρ G (Table III) , the fractional weight of glandular w G and adipose tissue w A can be estimated from
Although a mean breast density ρ is used to determine the fractional weight composition, the CT-based voxel mass densities are recommended.
Bone, possibly comprising bone marrow, is a special case with many possible compositions. Voxel mass density should be taken from CT images. The composition of cortical bone in Table III is recommended, but it should be pointed out that bone rarely plays an import role in brachytherapy dose calculations. In case another composition is used, it should be documented and a comparison with the composition of Table III should be provided for intercomparison purposes.
In case CT images are available, for all voxels outside contours, we recommend using the CT densities with a composition of "mean soft tissue" as defined in Table III . If adequately visualized and segmented, fat-like tissues can be contoured and used in the calculation. The mean adipose tissue listed in Table III may be used; if an alternative composition is used it should be documented.
IV.B.2.a. Use of other imaging modalities.
In case no CT images of the target geometry are available, the Task Group recommends:
r Using bulk tissue densities and compositions recommended previously based on contoured organs if possible.
r For LE brachytherapy, if US images are used (e.g., prostate seed implants), tissues outside the prostate contours should be set to mean soft tissues as described previously.
r For a multiple source implant, individual sources should be modeled.
r For HE sources (e.g., 192 Ir), MRI and US images can also be used provided that caution is exercised when extracting contours because of possible image distortions (MRI) and the nonquantitative nature of the image content. Furthermore, all tissues could be set either to the recommended bulk tissues densities and compositions from contours or alternatively to water with unit mass density. However, high-Z materials, such as applicators, should be taken into account as described in Sec. IV.B.1 and low-density media such as air must be included in the calculation to account for scatter conditions. Finally, it is expected that TPS vendors will provide easyto-use or automated tools to help clinical users accomplish these tasks.
IV.B.3. CT/CBCT artifact removal
For MBDCA dose calculations, it is recommended to first remove visible artifacts. In the simplest approach, a manual override of the tissue composition and density (see "Use of other imaging modalities" above) should be performed and documented. The use of advanced algorithms for artifact removal, as described in Sec. IV.A.5, is not the standard of care and should be used cautiously. For any application, the user shall clearly describe the CT artifact removal method used, if any.
IV.C. Areas of research
IV.C.1. Determination of tissue composition
The consensus list of tissue composition and density needs to be validated and refined. It needs to represent the tissues from typical cancer patients more accurately than the poorly validated recommendations from ICRU, ICRP, and other groups. Further experimental investigation into tissue compositions, including their interpatient and intraorgan variations, with an emphasis on dosimetric applications, is strongly encouraged. Research is needed to characterize prostate and breast calcifications more accurately. Tissue composition of organs in cancer patients and healthy subjects may not be the same. Ideally, the tissue composition and mass density of all voxels should be known for individual patients. With the current state-of-the-art in CT imaging, this has not yet been realized. Hence, further research into more sophisticated CT imaging methods such as dual-energy or spectral x-ray imaging and diffraction imaging is needed. Research into alternate quantitative imaging methods such as MRI and US is also needed.
IV.C.2. Segmentation methods
Research efforts are ongoing in DECT and spectral CT. Whether this constitutes an improvement over single-energy CT to derive tissue characteristics for brachytherapy dose calculations remains to be seen. 154, 155 HU calibration in kV-CBCT is an issue that deserves more attention before CBCT images can be used reliably for brachytherapy dose calculations taking tissue heterogeneities into account. Tissue segmentation methods based on feature recognition and/or anatomy atlases should also be pursued in brachytherapy.
IV.C.3. CT artifact removal
It is clear that robust CT artifact correction algorithms are needed for accurate LE brachytherapy MBDCA dose calculations. Most efforts have been devoted to improving image quality and pattern recognition. Specific research efforts for improving dose calculations are needed. These methods are not yet commonly available and their potential to improve dose accuracy needs to be established.
V. MBDCA COMMISSIONING
The commissioning of a brachytherapy TPS includes tasks outlined in the AAPM TG-40, TG-56, and TG-64 reports with specifics provided on HDR 192 Ir systems and LDR permanent prostate brachytherapy covered in TG-59 and TG-64, respectively. 39, [185] [186] [187] The majority of these recommendations address treatment-specific QA tasks, and all of these reports presume the AAPM TG-43 formalism. 3, 4 As the focus of this report is advanced brachytherapy dose calculation algorithms, this section will therefore focus only on QA tasks related to MBDCAs. Commissioning brachytherapy MBDCAs will have many aspects in common with TG-43-based systems, but will require algorithm-specific tasks described below.
V.A. Literature review
The literature is growing on MBDCAs and the dosimetric effects supporting their use for certain disease sites. However, to our knowledge, there is currently little literature providing quantitative information or practical guidance on the commissioning of brachytherapy MBDCAs for clinical use. [70] [71] [72] Consequently, there is an opportunity to establish uniform commissioning procedures for various MBDCAs and across institutions.
V.B. From TG-43 to MBDCA-based commissioning
The AAPM, ESTRO, ABS, and ABG recommend minimum commissioning standards that are designed to evaluate MBDCAs under conditions similar to those encountered in clinical brachytherapy practice, based on the established TG-43 dose calculation formalism and the new MBDCA. In this section, two levels of commissioning tests that should be performed in addition to TPS QC/QA recommendations already in place based on societal guidelines are described.
All code implementations of MC, CC, or GBBS methods as MBDCA dose engines involve compromises between computational speed and sufficient dose calculation accuracy and, therefore, the resulting solutions will have a certain amount of uncertainty. These code implementations must be carefully benchmarked against MC or experimentally when uncertainties adequately permit to ensure sufficiently accurate dose prediction within the intended domain.
V.B.1. MBDCA commissioning level 1
The AAPM TG-43 dose calculation formalism is based on the assumption that photon-emitting brachytherapy sources are cylindrically symmetric, enabling single-source dose distributions to be parameterized as functions of radial distance r and polar angle θ from the source long-axis in spherical, homogenous water phantoms having outer radii R of 15 cm and 40 cm for LE and HE photon emitters, respectively. Analogous to current TPS based on the TG-43 formalism, any TPS using a MBDCA should allow direct dose or dose rate comparisons using the same dose grid size of TG-43 to facilitate direct evaluation. The clinical medical physicist should determine agreement of MBDCA TPS-derived absolute dose or dose rate in comparison with the dose or dose rate produced in the TPS using the AAPM consensus TG-43 dosimetry parameters for a given brachytherapy source model. Furthermore, hand calculations should be performed for several points-of-interest covering the range of r and θ to be used in clinical practice. As recommended in the 2004 AAPM TG-43U1 report, a 2.0% tolerance should be used for agreement with AAPM consensus TG-43 dosimetry parameters. Any deviations >2.0% should be carefully examined (see Example 1) , and the clinical impact understood and documented before patient use.
A direct comparison of the MBDCA-based TPS output in a reference-sized homogenous water phantom to AAPM consensus data is helpful for physicists during transition to MBDCA-based TPS. Calculations should be conducted under reference conditions, i.e., water medium providing full scatter conditions, 99, 188 at distances up to 10 cm away from the source. Comparing TG-43 dosimetry parameters is a necessary first step since these parameters describe the spatial dose distribution due to the physical source model without significant consideration of the surrounding environment. An example of this comparison is shown below.
Example 1:
Mikell and Mourtada reported on the dose distributions of a HDR 192 Ir source in a homogeneous water geometry calculated using BrachyVision (BV) TPS (BrachyVision v8.8, Varian Medical Systems, Palo Alto, CA) with the MBDCAbased Acuros R system. 71 The percent dose difference (% D) of GBBS was determined for three cases:
(1) published TG-43 data, 189 (2) MCNPX simulations of the model VS2000 HDR 192 Ir source centered in a spherical water phantom of radius R = 15 cm, and (3) output from a TG-43-based TPS using vendor supplied F(r, θ ) tables.
Dose differences >20% between Acuros R and TG-43-based dosimetry near the source delivery cable were observed. This was attributed to Acuros R using a 0.1 cm long delivery cable, while the TG-43-based TPS algorithm used data based on a 15 cm long cable. While these dose differences were large near the cable, the impact on clinical outcomes was negligible with dose differences of less than 3% reported.
V.B.2. MBDCA commissioning level 2
Brachytherapy treatment planning that accounts for radiation scatter conditions and the radiological influence of material heterogeneities differing from liquid water is beyond the AAPM TG-43 dosimetry formalism. However, these effects are real and potentially produce clinically relevant differences between calculated dose distributions of TG-43-based and MBDCA-based TPS. Consequently, tests of these effects on TPS results are required. Comparisons of the 3D dose distributions calculated with the clinical MBDCA-based TPS on specific virtual phantoms mimicking clinical scenarios should be independently verified against benchmark dose distributions derived from the same phantom geometries. Based on the TPS dose output type, D m,m or D w,m , the independent dose calculation should be consistent with the TPS style option. At this time, clinical physicists should be aware that such benchmark dose distributions should only be obtained via the use of a well-documented MC code. Direct comparison of the MBDCA output to a reference treatment plan having identical heterogeneous conditions is mandatory for physicists to commission MBDCA-based TPS.
For LE photon-emitting brachytherapy sources such as 125 I, the influence of radiation backscatter is often negligible in comparison to the impact of varying tissue composition. For HE photon-emitting brachytherapy sources, such as 192 Ir, radiation scatter plays a major role. While variations in soft tissue composition cause minimal changes in dose calculation, applicators having components with mass density >2 g/cm 3 are dosimetrically important. For both energy regimes, any deviations between the MBDCA-based TPS results and the reference treatment plan should be documented, and the clinical significance understood. Example 2 for LE sources, and Examples 3 and 4 for HE sources, illustrate comparisons between reference (MC-based) treatment plans and MBDCA-based TPS results.
Example 2:
Dose distributions around the 16 mm COMS eye plaque, using a fixed geometry of 125 I seeds, have recently been examined by two independent groups. 22, 190 Both investigation teams calculated 3D D m,m dose distributions accounting for plaque material heterogeneities, but set the eye composition to liquid water. Dosimetric agreement on the plaque central-axis between these groups has recently been shown to be 0.991 ± 0.019 (k = 2). 191 The data of Melhus and Rivard were entered into the Pinnacle TPS using a MBDCA with a hybrid TG-43 MBDCA approach assuming cylindrically symmetric plaque dose distributions. 54 The TPS agreement with the reference data was 0.999 ± 0.004 (k = 2) for distances ranging from 0.0 to 24.3 mm from the plaque/eye interface along the plaque central-axis.
Example 3:
Zourari et al. tested a MBDCA-based TPS (Acuros R ) to account for the altered scatter conditions generated by the proximity of a HDR 192 Ir brachytherapy source to the boundary of a R = 15 cm water phantom in comparison to MC results. 70 Dose distributions with the source shifted 5 cm and 12.5 cm from the phantom center differed by more than 20% in comparison to the TG-43 results, but showed agreement within 3% (k = 2) of MC results, with the largest errors along the source long-axis.
Example 4:
Petrokokkinos et al. reported on the dosimetric validation of Acuros R for multiple 192 Ir source dwell position brachytherapy applications employing a shielded applicator in homogeneous water geometries. 72 Seven VS2000 HDR 192 Ir source dwell positions and a partially shielded applicator (GM11004380, Varian Brachytherapy, Charlottesville, VA) were compared to corresponding MC simulation results, as well as experimental results obtained using the VIP polymer gel-MRI three-dimensional dosimetry method with a custom-made phantom. The TPS and MC dose distributions were found in agreement, mostly within 2%. However, differences between the TPS and MC results (>2%) were observed at points in the penumbra of the shields (i.e., close to the edges of the "shielded" segment of the geometries). These differences were experimentally verified and therefore attributed to the TPS. Apart from these regions, experimental and TPS dose distributions were found in agreement within 2 mm distance-to-agreement and 5% individual point dose difference criteria.
V.B.3. MBDCA commissioning workflow
New clinical tools often require new workflows for proper integration into clinical practice. Figure 4 through expansion of the joint AAPM/RPC Brachytherapy Source Registry as described by Rivard et al. 99 This Registry currently houses a list of sources (both LE and HDR 192 Ir), which meet the minimum dosimetric prerequisites and calibration frequencies recommended by the AAPM. This Registry, or some complementary international counterpart, should be expanded to include quantitative data on brachytherapy source benchmarks in easily accessible electronic format to facilitate comparisons with TPS outputs from MBDCAs beyond the current approach of pointing medical physicists to the published literature. Further, test cases should be developed with uniformity amongst vendors (when appropriate) for inclusion in their commissioning test procedures to depict dose calculations with and without MBDCAs. However, such development is beyond the scope of this Task Group and is left as an area of research (Sec. V.C).
Having an independent repository to house the reference data (such as the Registry) would help facilitate this process efficiently-especially with international accessibility. By submitting engineering drawings of the source and source-applicator combinations, manufacturers will facilitate accuracy and ease of simulations to raise the standards for brachytherapy dose calculations.
V.B.3.b. DICOM test case importing.
During the MB-DCA TPS commissioning process, the physicist downloads and imports DICOM files of virtual phantoms as test cases (see above) from a secure website. Such files include the geometry, precontoured DICOM-RT ROIs, points-of-interest (POIs), the RT-Plan, explicit material definitions (for crosssection assignments) and a description of the source strength, dwell positions, dwell times, and other information as found in the DICOM-RT structure.
V.B.3.c. TG-43-based dose calculation tests.
Once the test case plan is imported, the first step is to copy the plan for comparison under TG-43 conditions. Reported POI results should be quantitatively compared to the plan report obtained from the Registry. This step allows for verification that all treatment plan parameters, such as source strength, loading configuration, match the test case plan prior to running the more complex MBDCA dose engine.
V.B.3.d. MBDCA-based dose calculation tests.
After the initial TG-43 plan verifications, the physicist copies the test case plan and reruns the dose calculation using the MBDCA. Using the TPS plan evaluation tools, comparisons between the reference data and the institutional results are made of ROI DVHs, POI doses, etc. If the MBDCA-based TPS allows users to insert a solid brachytherapy applicator in a plan, the physicist should use the TPS measuring tools (distance and angle rulers) to compare vendor drawings to the outer and inner dimensions in the applicator library. At a minimum, the physicist should measure a few dimensions of the applicator(s) used in the clinic with mechanical calipers or radiographic imaging. 186 Given established tolerances, the physicist will release the system for general clinical use or inclusion in cooperative clinical trials.
V.B.3.e. Reference CT scanner calibration data. An important input for the MBDCA-based TPS is the reference CT scanner calibration function, especially for LE brachytherapy sources as discussed in Sec. IV. The physicist should copy this calibration curve from the Registry for TPS entry. This is not intended to replace the institution's CT calibration curve but is only for the purpose of comparing to the reference datasets. Also, the physicist should verify that the materials used in the TPS are consistent with those provided in the test case.
V.B.3.f. Select dose scoring medium type. User should specify dose scoring medium (to medium or water) following the recommendation of Sec. IV.
V.C. Areas of research V.C.1. Workflow
The recommended commissioning workflow is general enough to be applicable to any MBDCA TPS. It contains multiple checks against the current, well-known TG-43 standard to ensure consistency of the process. However, commissioning of a MBDCA currently represents a particular challenge on multiple counts. Presently, there is only a single commercial MBDCA-based TPS available, Acuros R .
V.C.2. Test cases
It is not reasonable to validate MBDCA implementation for all possible combinations of source-applicator-geometry. Thus, exploring MBDCA limitations is an important undertaking among early adopters, [70] [71] [72] and must be expanded to various tumor sites and treatment geometries. It is expected that this exercise will be repeated for other MBDCAs as they become available. In this regard, creation of a Registry (proposed previously) should help early adopters as well as clinical medical physicists. Developers of new test cases are strongly encouraged to share their validation geometries through the Registry. To achieve this goal, TG-186 recommends creation of a Working Group with international membership. This Working Group will determine the submission modality or prerequisites, review submission prior to availability and propose a first set of test cases to help the community in this crucial process.
V.C.3. Gamma-index comparisons
It will be critical to refine the dose accuracy tolerance requirements for MBDCAs. The gamma-index concept (concurrently evaluating percentage agreement and distanceto-agreement) has been used for several years in EBRT dosimetry quality analysis. 192, 193 Considering a gammaindex metric for brachytherapy dosimetry is an important first step. A simple ±2% tolerance level dates from 1994. 185 The 2004 AAPM TG-43U1 report further recommended a 2% tolerance for agreement of reference dosimetry parameters and overall dose calculation. 4 However, a tolerance criterion has not been specified for the distance-to-agreement between the reference dataset and that being evaluated. Further, an explicit method for performing this evaluation over the range of all clinical points of interest was not specified.
Since then, a number of investigators have applied the gamma-index concept to brachytherapy. Yang et al. 56 compared MC dosimetry results for HDR 192 Ir breast applicator to those obtained using a TG-43 hybrid MBDCA approach and found a 99.24% gamma-index pass rate with 1% and 1 mm criterion, and a 99.95% pass rate for a 2% and 2 mm criterion. Petrokokkinos et al. 72 examined the accuracy of the Acuros R system in comparison to MCNPX-based MC simulations for the dose distribution from a HDR 192 Ir source in the presence of a shielded vaginal applicator. The large majority of points on the transverse and coronal planes met the gamma index 5% and 2 mm pass rate criterion. Bannon et al. examined 103 Pd and 192 Ir sources using a 0.5 mm dose grid and a 2% and 2 mm criterion, and obtained passing rates of 99.6% and 99.9% for linear sources and 98.9% and 100% for toroidal sources, respectively. 194 Based on this literature and observations made when creating the AAPM TG-43U1 report, a gamma index criterion of 2.0% and 2.0 mm with a ≥99% pass rate for clinically relevant points may generally be used to evaluate agreement of MBDCA-based TPS results with reference treatment plans. At the same time, setting tolerance levels is a major endeavor and the set of criteria for acceptability might need to be adjusted depending on the complexity of the case, such as in Venselaar et al. 195 Hence, more research, similar to the study by Stock et al. is needed to establish clear sets of criteria, 196 and further validation and cross comparison with MC and other MBDCAs should be a major area of research.
V.C.4. Phantom development
Finally, there is a need to design and implement relevant physical phantom geometries with known materials, possibly adding various applicator/shield inserts. For these phantoms, it is necessary to assess the dose distributions experimentally (e.g., using TLDs, radiochromic film, or GEL dosimeters) and compare the results with a virtual representation within a MB-DCA TPS. 72 This process would generate sets of "true" independent reference data against which clinical medical physicists can validate their TPS and for which new systems can be benchmarked. Again, the proposed Registry would play a central role in this process.
VI. OTHER ISSUES AND LIMITATIONS
VI.A. Uncertainties related to MBDCA
There are several sources of MBDCA dosimetric uncertainties; many are common to all calculation methods. In this section, both general and method-specific dosimetric uncertainties are identified. A list of dosimetric uncertainty components in approximate chronological order is given in Table IV , and includes several items and expands upon those from the joint AAPM/ESTRO TG-138 report for direct MC simulations of brachytherapy source dosimetry. 197 While quantitative uncertainties are not recommended due to the paucity of the literature on this topic and the variability of results based on different possibilities of applicator/source/site, an indication of which items are generally guided by MBDCA design or the physicist is made available. Based on presently available choices within the TPS, responsibility for some of these components may fall to the medical physicist.
For all MBDCA approaches to brachytherapy treatment planning, Type B dosimetric uncertainties (nonstatistical or systematic) are present. Specific to MC methods, statistical, or Type A, uncertainties become more pronounced with limited particle histories, while Type B uncertainties may occur if certain variance reduction techniques are used, which introduce biases, such as the MC condensed-history algorithm for charged particle transport. Specific to GBBS Use of collision kerma versus absorbed dose, especially in tissue areas where CPE assumption is not true (near interfaces of applicator and gas/tissue interface).
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Output voxel grid resolution size. Physicist methods, systematic uncertainties arise from spatial, angular, and energy discretization due to use of a finite grid. Specific to CC methods, systematic uncertainties arise from the use of angular discretization (i.e., collapsed point-spread kernels) combined with a finite grid. MBDCAs using MC or GBBS methods are similar as both methods converge to the LBTE solution. Therefore, uncertainties for MC and GBBS can be reduced by increasing the number of particles or the resolution in space, angle, and energy, respectively. Based on point-kernel superposition, 9, 10, 16, 57, 58, 198, 199 the CC method involves no approximations up to and including the dose from once scattered photons. However, dose from multiply scattered photons calculated by CC involves an approximation related to phantom size from initial generation of point kernels for multiply scattered photons and use of rectilinear methods to scale the multiple-scatter kernel for material heterogeneities. Dosimetric uncertainties for MC, GBBS, and CC usually increase with increasing distance from the source and with decreasing voxel dimensions, and can be reduced at the expense of increased calculation time through use of more histories (MC) or denser grids (GBBS, CC).
In trying to limit some of these uncertainties, a calculation voxel size no larger than (2 mm) 3 should be used at all times. If allowed by the imaging data set resolution, smaller voxel sizes [< (1 mm) 3 ] could be used. This would be of particular interest in close proximity to sources and interfaces. Furthermore, dose uncertainties obtained using MC MBDCAs for the volume of interest (e.g., CTV, PTV, etc.) should be reported systematically. For the time being, the approach of Sec. III.D.1 of TG-105 (Ref. 85 ) is recommended, with a threshold of using voxels with dose values 25% or greater than the prescription dose. This change in threshold is needed since brachytherapy has steeper dose gradients than EBRT.
VI.B. Limitations
There may be certain limitations imposed by each of the MBDC engines as implemented in TPS software. Examples of such limitations include:
(1) Limits on which brachytherapy seeds are supported. Through coordination amongst clinical professional societies, TPS vendors, and source manufacturers, it is hoped that many of the current limitations will be overcome in the near future.
VI.C. Considerations for changing brachytherapy dose prescriptions
There is a long history in the field of brachytherapy of safely changing prescriptions based on dosimetric advancements. Source strength units have evolved from mg-Ra-eq to apparent activity to air-kerma strength, S K and reference air-kerma rate, the currently accepted two measures of source strength for LE and HE photon-emitting brachytherapy sources. 200 These changes have primarily resulted in prescriptions using absorbed dose instead of specification in terms of source strength and implant duration. More recently, establishment of the AAPM TG-43 formalism and migration of the LE S K standard to the NIST WAFAC has resulted in prescription dose changes of about −10% for LDR 125 I seeds, with permanent prostate implant prescriptions changing from 160 Gy to 145 Gy, 201 and COMS eye plaque application prescriptions from 100 Gy to 85 Gy. 202 Further, when accounting for COMS eye plaque material heterogeneities and radiation scatter conditions between D w,w-TG43 and D w,m , the prescribed dose of 85 Gy corresponds to an administered dose of 76 Gy for 125 I (−11%) and 67 Gy for 103 Pd (−21%) sources. 191 Such large dose changes are not expected for HE photon-emitting brachytherapy sources.
A dose tolerance of ±5% was adopted by the ABS for addressing dosimetric changes upon implementing dosimetry recommendations of the 2004 AAPM TG-43U1 report. 4, 5, 203, 204 As more data become available on differences between prescribed and administered doses, the brachytherapy community will be better positioned to evaluate whether prescription changes are warranted for specific disease-sites.
Based on the significance of heterogeneity effects, the AAPM, ESTRO, ABS, and ABG recommend for those clinics that have the necessary resources that dose calculations be performed not only according to the TG-43 formalism, but also using the more accurate heterogeneous calculations. For the latter, the recommendations made in the previous sections should be followed closely. These dose estimates should be kept on file for a clinical evaluation in anticipation of sufficient heterogeneity-enabled brachytherapy TPS. While there remain significant dosimetric uncertainties and limitations as examined in Subsections VI.A and VI.B, the capabilities of MBDCAs to account for material heterogeneities, patient scatter conditions, and attenuation amongst sources and by high-Z applicators require the radiation oncologist to assess the clinical practice of brachytherapy using MBDCAbased dosimetry. Until sufficient clinical data become available to issue specific societal recommendations on dose prescriptions, the AAPM, ESTRO, ABS, and ABG recommend that prescriptions based on the TG-43 dose calculation formalism remain in effect. Similarly, for the time being MBDCAs are generally impractical (from a computational time perspective) for dose optimization and the TG-43 formalism remains the standard of practice for this task.
VII. CONCLUSIONS
The AAPM TG-43 dose calculation formalism has provided the brachytherapy community with clear processes in terms of source strength specification and efficient dose calculations that made it easier to compare dose-outcome relationships among different institutions. For the time being, the TG-43 formalism will remain an important part of clinical brachytherapy. This report recognizes the benefit of the current standard and has built upon the developed infrastructure with specific recommendations to help move the brachytherapy field towards greater adoption of more accurate, advanced model-based dose calculation algorithms. Application of TG-186 guidance should help to ensure that the shared worldwide experience in using the TG-43 formalism is not lost in the process of seeking better brachytherapy dose calculation tools. The report also underlines specific research areas that brachytherapy physicists and physicians should tackle expeditiously, perhaps through consortium efforts to provide data required to move forward with MBDCAs.
Furthermore, it is important to acknowledge that the bulk of clinical brachytherapy dosimetry experience is with radiation transport and energy deposition in water, with dose to water reported (as calculated under the TG-43 approach). Hence, for the time being the recommendation that TG-43 calculations be performed in parallel with model-based dose calculations is crucial. Only in this way will the radiation therapy community become familiar with dose differences, including the impact on prescription dose and doses to points, organs, and regions of interest. This will enable assessment of the implications of adopting MBDCAs for treatment planning, and help the brachytherapy community to understand new study results and place them in the context of previous dose calculations, treatment planning, and research.
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